文献速递药物相互作用肝肾功能剂量调整治疗药物监测与药物基因组学

健康志愿者中鉴定评估MATE介导药物相互作用风险的合适内源性生物标志物

Identification of Appropriate Endogenous Biomarker for Risk Assessment of Multidrug and Toxin Extrusion Protein-Mediated Drug-Drug Interactions in Healthy Volunteers.
PubMed 文献 · Clin Pharmacol Ther · 2020-10-09

结果显示1-NMN和m1 A的肾清除率变化与二甲双胍肾清除率变化良好相关,而肌酐相关性差;基于非线性回归获得的体内Ki与体外MATE1/2-K的Ki可比。结论认为1-NMN和m1 A的肾清除率可作为定量MATE1/2-K生物标志物用于健康志愿者DDI风险评估。

要点

  • 1-NMN和m1 A的肾清除率变化与二甲双胍肾清除率变化良好相关,优于肌酐。
  • 乙胺嘧啶剂量依赖性地降低1-NMN、m1 A和肌酐的肾清除率。
  • 体内估算的乙胺嘧啶Ki经游离分数校正后与体外MATE1/2-K的Ki可比。

核心结论

  • 1-NMN和m1 A的肾清除率可作为定量MATE1/2-K介导DDI风险的生物标志物用于健康志愿者。

主要发现

  • 1-NMN和m1 A的肾清除率随乙胺嘧啶剂量变化与二甲双胍肾清除率变化良好相关。
  • 肌酐的肾清除率被乙胺嘧啶降低,但其变化与二甲双胍肾清除率变化相关性差。
  • 非线性回归分析(肾清除率对血浆乙胺嘧啶平均总浓度)估算出乙胺嘧啶的抑制常数Ki及对乙胺嘧啶敏感的清除途径分数。
  • 体内Ki经血浆游离分数转换为游离Ki后,与体外MATE1(1-NMN)和MATE2-K(1-NMN和m1 A)的Ki可比。

临床怎么用

  • 在健康志愿者DDI风险评估中,可考虑将1-NMN和m1 A的肾清除率作为MATE1/2-K的定量生物标志物。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Endogenous biomarkers are emerging to advance clinical drug-drug interaction (DDI) risk assessment in drug development. Twelve healthy subjects received a multidrug and toxin exclusion protein (MATE) inhibitor (pyrimethamine, 10, 25, and 75 mg) in a crossover fashion to identify an appropriate endogenous biomarker to assess MATE1/2-K-mediated DDI in the kidneys. Metformin (500 mg) was also given as reference probe drug for MATE1/2-K. In addition to the previously reported endogenous biomarker candidates (creatinine and N1 -methylnicotinamide (1-NMN)), N1 -methyladenosine (m1 A) was included as novel biomarkers. 1-NMN and m1 A presented as superior MATE1/2-K biomarkers since changes in their renal clearance (CLr ) along with pyrimethamine dose were well-correlated with metformin CLr changes. The CLr of creatinine was reduced by pyrimethamine, however, its changes poorly correlated with metformin CLr changes. Nonlinear regression analysis (CLr vs. mean total concentration of pyrimethamine in plasma) yielded an estimate of the inhibition constant (Ki ) of pyrimethamine and the fraction of the clearance pathway sensitive to pyrimethamine. The in vivo Ki value thus obtained was further converted to unbound Ki using plasma unbound fraction of pyrimethamine, which was comparable to the in vitro Ki for MATE1 (1-NMN) and MATE2-K (1-NMN and m1 A). It is concluded that 1-NMN and m1 A CLr can be leveraged as quantitative MATE1/2-K biomarkers for DDI risk assessment in healthy volunteers.

来源:Clin Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Miyake T, Kimoto E, Luo L, et al. Identification of Appropriate Endogenous Biomarker for Risk Assessment of Multidrug and Toxin Extrusion Protein-Mediated Drug-Drug Interactions in Healthy Volunteers. Clin Pharmacol Ther. 2020. PMID: 32866300. doi:10.1002/cpt.2022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。